

# CITATION REPORT

List of articles citing

## DNMT3A mutations in myeloproliferative neoplasms

DOI: 10.1038/leu.2011.77  
Leukemia, 2011, 25, 1217-9.

**Source:** <https://exaly.com/paper-pdf/51036379/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
143	Uses and abuses of JAK2 and MPL mutation tests in myeloproliferative neoplasms a paper from the 2010 William Beaumont hospital symposium on molecular pathology. <i>Journal of Molecular Diagnostics</i> , <b>2011</b> , 13, 461-6	5.1	16
142	Genetic and epigenetic complexity in myeloproliferative neoplasms. <b>2011</b> , 2011, 208-14		84
141	Recurrent DNMT3A R882 mutations in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome. <i>PLoS ONE</i> , <b>2011</b> , 6, e26906	3.7	104
140	Mutations galore in myeloproliferative neoplasms: would the real Spartacus please stand up?. <i>Leukemia</i> , <b>2011</b> , 25, 1059-63	10.7	27
139	DNMT3A Mutations in Patients with Acute Myeloid Leukemia in South Brazil. <b>2012</b> , 2012, 697691		10
138	Biology and clinical management of myeloproliferative neoplasms and development of the JAK inhibitor ruxolitinib. <b>2012</b> , 19, 4399-413		71
137	Frequency, onset and clinical impact of somatic DNMT3A mutations in therapy-related and secondary acute myeloid leukemia. <i>Haematologica</i> , <b>2012</b> , 97, 246-50	6.6	43
136	Essential thrombocythemia: new advances in an old disease. <b>2012</b> , 2, 603-614		1
135	Myeloproliferative neoplasm animal models. <b>2012</b> , 26, 1065-81		27
134	Role of additional novel therapies in myeloproliferative neoplasms. <b>2012</b> , 26, 959-80		6
133	The role of mutations in epigenetic regulators in myeloid malignancies. <b>2012</b> , 12, 599-612		535
132	Genotype-phenotype interactions in the myeloproliferative neoplasms. <b>2012</b> , 26, 993-1015		5
131	Current outlook on molecular pathogenesis and treatment of myeloproliferative neoplasms. <b>2012</b> , 16, 269-83		13
130	Insights into the molecular genetics of myeloproliferative neoplasms. <b>2012</b> , 411-8		4
129	The role of HMGA2 in the proliferation and expansion of a hematopoietic cell in myeloproliferative neoplasms. <b>2012</b> , 58, 91-100		11
128	Recent developments in myelofibrosis. <b>2012</b> , 125		2
127	Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association. <i>Leukemia</i> , <b>2012</b> , 26, 1247-54	10.7	109

126	DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications. <i>Blood</i> , <b>2012</b> , 119, 559-68	2.2	180
125	Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms. <b>2012</b> , 51, 743-55		119
124	Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: proceedings from the 6th International Post-ASH Symposium. <b>2012</b> , 87, 562-8		18
123	JAK2 and genomic instability in the myeloproliferative neoplasms: a case of the chicken or the egg?. <b>2012</b> , 87, 1028-36		19
122	Clonal and lineage analysis of somatic DNMT3A and JAK2 mutations in a chronic phase polycythemia vera patient. <b>2012</b> , 156, 268-70		10
121	DNMT3A mutations are rare in childhood acute myeloid leukaemia, myelodysplastic syndromes and juvenile myelomonocytic leukaemia. <b>2012</b> , 156, 413-4		18
120	Absence of DNMT3A gene mutation in chronic myeloid leukemia patients in blast crisis. <b>2012</b> , 88, 455-7		2
119	Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies. <b>2012</b> , 87, 245-50		79
118	Disordered epigenetic regulation in the pathophysiology of myeloproliferative neoplasms. <i>Current Hematologic Malignancy Reports</i> , <b>2012</b> , 7, 34-42	4.4	7
117	Mutational analysis of DNMT3A gene in acute leukemias and common solid cancers. <b>2013</b> , 121, 85-94		42
116	Role of DNMT3A, TET2, and IDH1/2 mutations in pre-leukemic stem cells in acute myeloid leukemia. <b>2013</b> , 98, 648-57		85
115	Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon $\alpha$ . <i>Blood</i> , <b>2013</b> , 122, 893-901	2.2	156
114	DNA methyltransferases in hematologic malignancies. <b>2013</b> , 50, 48-60		36
113	Mutation and Lineage Analysis of DNMT3A in BCR-ABL1-negative Chronic Myeloproliferative Neoplasms. <b>2013</b> , 7, 186-188		5
112	The biology and clinical impact of genetic lesions in myeloid malignancies. <i>Blood</i> , <b>2013</b> , 122, 3741-8	2.2	37
111	Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. <b>2013</b> , 369, 2391-2405		1262
110	Genetic basis of MPN: Beyond JAK2-V617F. <i>Current Hematologic Malignancy Reports</i> , <b>2013</b> , 8, 299-306	4.4	15
109	A DNMT3A mutation common in AML exhibits dominant-negative effects in murine ES cells. <i>Blood</i> , <b>2013</b> , 122, 4086-9	2.2	126

108	Emerging drugs for polycythemia vera. <b>2013</b> , 18, 393-404		7
107	Laboratory practice guidelines for detecting and reporting JAK2 and MPL mutations in myeloproliferative neoplasms: a report of the Association for Molecular Pathology. <i>Journal of Molecular Diagnostics</i> , <b>2013</b> , 15, 733-44	5.1	34
106	Genetic and epigenetic alterations of myeloproliferative disorders. <b>2013</b> , 97, 183-97		47
105	Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management. <b>2013</b> , 88, 507-16		92
104	Hematopoietic stem cells, progenitor cells and leukemic stem cells in adult myeloproliferative neoplasms. <b>2013</b> , 54, 922-33		6
103	Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group. <b>2013</b> , 31, 95-103		74
102	Focus on the epigenome in the myeloproliferative neoplasms. <b>2013</b> , 2013, 538-44		11
101	Dual PI3K/AKT/mTOR inhibitor BEZ235 synergistically enhances the activity of JAK2 inhibitor against cultured and primary human myeloproliferative neoplasm cells. <b>2013</b> , 12, 577-88		85
100	Molecular basis and clonal evolution of myeloproliferative neoplasms. <b>2013</b> , 51, 1889-96		7
99	Inherited predisposition to myeloproliferative neoplasms. <b>2013</b> , 4, 237-53		40
98	Gene expression profiling of the DNMT3A R882 mutation in acute leukemia. <b>2013</b> , 6, 268-274		12
97	The molecular basis of acute myeloid leukemia. 751-768		
96	Mutation analysis of JAK2V617F, FLT3-ITD, NPM1, and DNMT3A in Chinese patients with myeloproliferative neoplasms. <b>2014</b> , 2014, 485645		6
95	The evolving genomic landscape of myeloproliferative neoplasms. <b>2014</b> , 2014, 287-96		51
94	Epigenetics in the hematologic malignancies. <i>Haematologica</i> , <b>2014</b> , 99, 1772-83	6.6	48
93	Genetics of myeloproliferative neoplasms. <b>2014</b> , 20, 61-5		38
92	Transcriptional and Epigenetic Mechanisms Regulating Normal and Aberrant Blood Cell Development. <i>Epigenetics and Human Health</i> , <b>2014</b> ,		1
91	DNMT3A R882 mutations in patients with cytogenetically normal acute myeloid leukemia and myelodysplastic syndrome. <b>2014</b> , 53, 61-6		13

90	A primer on genomic and epigenomic alterations in the myeloproliferative neoplasms. <b>2014</b> , 27, 83-93		11
89	The mutation profile of JAK2 and CALR in Chinese Han patients with Philadelphia chromosome-negative myeloproliferative neoplasms. <b>2014</b> , 7, 48		32
88	Driver mutations of cancer epigenomes. <b>2014</b> , 5, 265-96		110
87	DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies. <i>Leukemia</i> , <b>2014</b> , 28, 1774-83	10.7	184
86	Chronic myelogenous leukemia, version 1.2015. <b>2014</b> , 12, 1590-610		42
85	Molecular diagnostics of myeloproliferative neoplasms. <b>2015</b> , 95, 270-9		56
84	DNMT3A mutations occur early or late in patients with myeloproliferative neoplasms and mutation order influences phenotype. <i>Haematologica</i> , <b>2015</b> , 100, e438-42	6.6	70
83	Enforced differentiation of Dnmt3a-null bone marrow leads to failure with c-Kit mutations driving leukemic transformation. <i>Blood</i> , <b>2015</b> , 125, 619-28	2.2	72
82	Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib. <i>Blood</i> , <b>2015</b> , 126, 790-7	2.2	130
81	HSP90 and HSP70: Implication in Inflammation Processes and Therapeutic Approaches for Myeloproliferative Neoplasms. <b>2015</b> , 2015, 970242		57
80	5-hydroxymethylcytosine in cancer: significance in diagnosis and therapy. <b>2015</b> , 208, 167-77		59
79	Tetraspanin CD9 participates in dysmegakaryopoiesis and stromal interactions in primary myelofibrosis. <i>Haematologica</i> , <b>2015</b> , 100, 757-67	6.6	6
78	DNMT3A in haematological malignancies. <b>2015</b> , 15, 152-65		298
77	Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management. <b>2015</b> , 90, 162-73		166
76	Clinical and molecular genetic characterization of myelofibrosis. <b>2015</b> , 22, 177-83		12
75	Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms. <b>2015</b> , 6, 6691		120
74	TET proteins and 5-methylcytosine oxidation in hematological cancers. <b>2015</b> , 263, 6-21		134
73	The role of mutations in epigenetic regulators in myeloid malignancies. <b>2015</b> , 263, 22-35		40

72	Clinical Manifestation of Calreticulin Gene Mutations in Essential Thrombocythemia without Janus Kinase 2 and MPL Mutations: A Chinese Cohort Clinical Study. <b>2016</b> , 129, 1778-83			3
71	. <b>2016</b> ,			2
70	Therapeutic approaches in myelofibrosis and myelodysplastic/myeloproliferative overlap syndromes. <b>2016</b> , 9, 2273-86			4
69	Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learned. <b>2016</b> , 9, 4937-57			11
68	Genetic Characteristics of Polycythemia Vera and Essential Thrombocythemia in Korean Patients. <b>2016</b> , 30, 1061-1070			
67	Pathogenesis of Myeloproliferative Disorders. <b>2016</b> , 11, 101-26			21
66	Molecular genetics of the myeloproliferative neoplasms. <b>2016</b> , 80-132			
65	Epigenetics of hematopoiesis and hematological malignancies. <b>2016</b> , 30, 2021-2041			79
64	Rapid Molecular Profiling of Myeloproliferative Neoplasms Using Targeted Exon Resequencing of 86 Genes Involved in JAK-STAT Signaling and Epigenetic Regulation. <i>Journal of Molecular Diagnostics</i> , <b>2016</b> , 18, 707-718	5.1		12
63	Prognosis of Primary Myelofibrosis in the Genomic Era. <b>2016</b> , 16 Suppl, S105-13			11
62	The Spectrum and Clinical Impact of Epigenetic Modifier Mutations in Myeloma. <b>2016</b> , 22, 5783-5794			56
61	Primary myelofibrosis: current therapeutic options. <b>2016</b> , 38, 257-63			5
60	Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia. <b>2016</b> , 6, e393			80
59	New Strategies in Myeloproliferative Neoplasms: The Evolving Genetic and Therapeutic Landscape. <b>2016</b> , 22, 1037-47			10
58	DNA methylation in normal and malignant hematopoiesis. <b>2016</b> , 103, 617-26			23
57	Clinicopathologic Effect of DNMT3A Mutation in Adult T-Cell Acute Lymphoblastic Leukemia. <b>2016</b> , 16, 43-8			3
56	DNMT3A, TET2, and JAK2 mutations in polycythemia vera following long-term remission of secondary acute myeloid leukemia. <b>2016</b> , 57, 1969-73			3
55	Dnmt3a regulates myeloproliferation and liver-specific expansion of hematopoietic stem and progenitor cells. <i>Leukemia</i> , <b>2016</b> , 30, 1133-42	10.7		43

54	DNMT3A R882 Mutation with FLT3-ITD Positivity Is an Extremely Poor Prognostic Factor in Patients with Normal-Karyotype Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation. <b>2016</b> , 22, 61-70		29
53	Management of myelofibrosis: JAK inhibition and beyond. <b>2017</b> , 10, 459-477		8
52	Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. <i>Blood</i> , <b>2017</b> , 129, 667-679	2.2	275
51	Molecular determinants of pathogenesis and clinical phenotype in myeloproliferative neoplasms. <i>Haematologica</i> , <b>2017</b> , 102, 7-17	6.6	44
50	DNMT3A in Leukemia. <i>Cold Spring Harbor Perspectives in Medicine</i> , <b>2017</b> , 7,	5.4	82
49	The spectrum of DNMT3A variants in Tatton-Brown-Rahman syndrome overlaps with that in hematologic malignancies. <b>2017</b> , 173, 3022-3028		24
48	Mutations in myeloproliferative neoplasms - their significance and clinical use. <b>2017</b> , 10, 961-973		17
47	DNMT3A mutations are associated with inferior overall and leukemia-free survival in chronic myelomonocytic leukemia. <b>2017</b> , 92, 56-61		48
46	After 10years of JAK2V617F: Disease biology and current management strategies in polycythaemia vera. <b>2017</b> , 31, 101-118		13
45	Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis. <i>Leukemia</i> , <b>2017</b> , 31, 889-895	10.7	11
44	Hmga2 collaborates with V617F in the development of myeloproliferative neoplasms. <b>2017</b> , 1, 1001-1015		10
43	The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation. <i>Internal Medicine</i> , <b>2017</b> , 56, 1705-1710	1.1	2
42	Genetic alterations crossing the borders of distinct hematopoietic lineages and solid tumors: Diagnostic challenges in the era of high-throughput sequencing in hemato-oncology. <i>Critical Reviews in Oncology/Hematology</i> , <b>2018</b> , 126, 64-79	7	6
41	Accelerating myelofibrosis through loss of. <i>Blood</i> , <b>2018</b> , 132, 2703-2704	2.2	2
40	Tropism of PCNSL: is it all about autoantigens?. <i>Blood</i> , <b>2018</b> , 132, 2704-2706	2.2	3
39	Jak2V617F and Dnmt3a loss cooperate to induce myelofibrosis through activated enhancer-driven inflammation. <i>Blood</i> , <b>2018</b> , 132, 2707-2721	2.2	37
38	Epigenetic Priming in Cancer Initiation. <i>Trends in Cancer</i> , <b>2018</b> , 4, 408-417	12.5	55
37	Study of DNA methyl transferase 3A mutation in acute myeloid leukemic patients. <i>Egyptian Journal of Medical Human Genetics</i> , <b>2018</b> , 19, 315-319	2	3

36	Epigenetic mechanisms as a new approach in cancer treatment: An updated review. <i>Genes and Diseases</i> , <b>2018</b> , 5, 304-311	6.6	100
35	Clinical Significance of DNA Variants in Chronic Myeloid Neoplasms: A Report of the Association for Molecular Pathology. <i>Journal of Molecular Diagnostics</i> , <b>2018</b> , 20, 717-737	5.1	28
34	DNA methylation as a transcriptional regulator of the immune system. <i>Translational Research</i> , <b>2019</b> , 204, 1-18	11	62
33	Philadelphia-Negative Myeloproliferative Neoplasms: Laboratory Workup in the Era of Next-Generation Sequencing. <i>Current Hematologic Malignancy Reports</i> , <b>2019</b> , 14, 376-385	4.4	1
32	Mutations in the DNMT3A DNA methyltransferase in acute myeloid leukemia patients cause both loss and gain of function and differential regulation by protein partners. <i>Journal of Biological Chemistry</i> , <b>2019</b> , 294, 4898-4910	5.4	34
31	mutation is associated with increased age and adverse outcome in adult T-cell acute lymphoblastic leukemia. <i>Haematologica</i> , <b>2019</b> , 104, 1617-1625	6.6	18
30	Heterogeneity in myeloproliferative neoplasms: Causes and consequences. <i>Advances in Biological Regulation</i> , <b>2019</b> , 71, 55-68	6.2	23
29	The Molecular Genetics of Myeloproliferative Neoplasms. <i>Cold Spring Harbor Perspectives in Medicine</i> , <b>2020</b> , 10,	5.4	19
28	De novo methyltransferases: Potential players in diseases and new directions for targeted therapy. <i>Biochimie</i> , <b>2020</b> , 176, 85-102	4.6	8
27	Preleukemic stem cells: leave it or not?. <i>Blood Science</i> , <b>2020</b> , 2, 54-58	0.9	0
26	Clonal Hematopoiesis and Mutations of Myeloproliferative Neoplasms. <i>Cancers</i> , <b>2020</b> , 12,	6.6	3
25	Murine Models of Myelofibrosis. <i>Cancers</i> , <b>2020</b> , 12,	6.6	8
24	Genetic and Genomic Landscape of Secondary and Therapy-Related Acute Myeloid Leukemia. <i>Genes</i> , <b>2020</b> , 11,	4.2	11
23	Does the order of mutational acquisition in myeloproliferative neoplasms matter? Evidence from JAK2 exon 12 and DNMT3A co-mutant polycythemia vera. <i>Journal of Hematopathology</i> , <b>2020</b> , 13, 105-109	4	1
22	Disease modifying agents of myeloproliferative neoplasms: a review. <i>Blood Research</i> , <b>2021</b> , 56, S26-S33	1.4	3
21	The interplay between DNA and histone methylation: molecular mechanisms and disease implications. <i>EMBO Reports</i> , <b>2021</b> , 22, e51803	6.5	12
20	Hydroxycarbamide effects on DNA methylation and gene expression in myeloproliferative neoplasms. <i>Genome Research</i> , <b>2021</b> , 31, 1381-1394	9.7	1
19	Neoplastische Bildungsstufen der Hämatoopoiese mit erhaltener Ausreifung. <b>2019</b> , 47-87		2



18	EZH2 mutations are related to low blast percentage in bone marrow and -7/del(7q) in de novo acute myeloid leukemia. <i>PLoS ONE</i> , <b>2013</b> , 8, e61341	3.7	46
17	Recent insights regarding the molecular basis of myeloproliferative neoplasms. <i>Korean Journal of Internal Medicine</i> , <b>2020</b> , 35, 1-11	2.5	14
16	Molecular Profile of BCR-ABL1 Negative Myeloproliferative Neoplasms and Its Impact on Prognosis and Management. <i>Advances in Molecular Pathology</i> , <b>2021</b> , 4, 65-79	0.3	
15	Update on the Biology of Myeloproliferative Neoplasms. <b>2012</b> , 3-10		
14	MOLECULAR PATHOGENESIS OF MYELOPROLIFERATIVE NEOPLASMS -THE ROLE OF HIGH MOBILITY GROUP AT-hook2 (HMGA2)-. <i>Japanese Journal of Transfusion and Cell Therapy</i> , <b>2012</b> , 58, 441-447	0.2	
13	Role of DNA Methyltransferases and DNA Methylation in Cell Fate Decisions During Blood Cell Development and Leukemia. <i>Epigenetics and Human Health</i> , <b>2014</b> , 205-219		
12	New Horizons in Myeloproliferative Neoplasms Treatment: A Review of Current and Future Therapeutic Options. <i>Medicina (Lithuania)</i> , <b>2021</b> , 57,	3.1	
11	Genetic Landscape of Myeloproliferative Neoplasms with an Emphasis on Molecular Diagnostic Laboratory Testing. <i>Life</i> , <b>2021</b> , 11,	3	1
10	Recurring mutations in myeloproliferative neoplasms alter epigenetic regulation of gene expression. <i>American Journal of Cancer Research</i> , <b>2011</b> , 1, 752-62	4.4	2
9	Molecular genetics of myelofibrosis and its associated disease phenotypes. <i>Translational Medicine @ UniSa</i> , <b>2014</b> , 8, 53-64	0.5	6
8	Digital-droplet PCR assays for IDH, DNMT3A and driver mutations to monitor after allogeneic stem cell transplantation minimal residual disease of myelofibrosis.. <i>Bone Marrow Transplantation</i> , <b>2022</b> ,	4.4	0
7	Mutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN.. <i>International Review of Cell and Molecular Biology</i> , <b>2022</b> , 366, 83-124	6	2
6	Understanding Aberrant Signaling to Elude Therapy Escape Mechanisms in Myeloproliferative Neoplasms.. <i>Cancers</i> , <b>2022</b> , 14,	6.6	
5	Heterozygous Dnmt3a R878C Induces Expansion of Quiescent Hematopoietic Stem Cell Pool.. <i>Experimental Hematology</i> , <b>2022</b> ,	3.1	
4	Molecular Pathogenesis of Myeloproliferative Neoplasms: From Molecular Landscape to Therapeutic Implications.. <i>International Journal of Molecular Sciences</i> , <b>2022</b> , 23,	6.3	1
3	Lysine-Specific Demethylase 1 (LSD1/KDM1A) Inhibition as a Target for Disease Modification in Myelofibrosis. <i>Cells</i> , <b>2022</b> , 11, 2107	7.9	1
2	Myeloproliferative Neoplasms. <b>2022</b> ,		0
1	The Role of DNA Methylation and DNA Methyltransferases in Cancer. <b>2022</b> , 317-348		1

